28.50
+5.56%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanobiotix
Its shares trade on Euronext Paris under the ticker NANO.PA. It has been listed since 29 October 2012. In the fiscal year to 31 December 2025, it reported revenue of €29.6m and a net loss of €24.0m. At that date it held total assets of €67.8m and shareholders' equity of −€84.5m.
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Oct 2012
- Employees
- 98
- Website
- nanobiotix.com ↗
Leadership
Pay as last reported
- Dr. Gary M. PhillipsIndependent Chairman of the Board€63,000
- Dr. Laurent LevyChief Executive Officer€667,396
- Ms. Anne-Marie GraffinIndependent Vice Chairwoman of the of the Board€42,000
- Mr. Bart Van RhijnChief Financial & Business Officer€563,444
- Ms. Anne-Juliette HermantChief Human Resources Officer€309,750
- Mr. Craig WestSenior Vice President - Investor Relations
- Ms. Anne-Sophie LariviereVice President - Strategy & Operational Excellence
- Mr. Brandon OwensVice President - Strategic Marketing and Corporate Communications
- Dr. Louis KayitalireChief Medical Officer€152,823
- Ms. Margaret LiuDirector
- Ms. Anat NaschitzDirector
- Dr. Alain HerreraIndependent Director€35,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nanobiotix SA possesses cutting-edge technology, enabling the development of novel therapeutics and diagnostics that have the potential to revolutionize the healthcare industry.
- The company holds a robust portfolio of patents, trademarks, and intellectual property rights, providing a competitive advantage and safeguarding their innovative products from competitors' imitation.
Weaknesses
- Nanobiotix SA currently has a limited presence in the global market, which restricts its reach and potential customer base.
- The company invests a significant amount of resources in research and development efforts, which can pose financial challenges, especially if expected outcomes are not achieved.
Opportunities
- The increasing need for advanced and effective therapeutics creates a favorable market environment for Nanobiotix SA to expand its product offerings and capture a larger market share.
- The company can explore partnerships with pharmaceutical companies or research institutions to leverage their expertise, gain access to additional resources, and accelerate the development and commercialization of its products.
Threats
- The healthcare industry is highly competitive, with numerous companies vying for market share. This poses a threat to Nanobiotix SA's ability to differentiate its products and maintain a competitive edge.
- Compliance with stringent regulations and obtaining necessary approvals can be time-consuming and expensive, potentially delaying the company's product launches and hindering its growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.